Pediatric acute myeloid leukemia: towards high-quality cure of all patients
- 1 November 2007
- journal article
- review article
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 92 (11), 1519-1532
- https://doi.org/10.3324/haematol.11203
Abstract
Prognosis of childhood acute myeloid leukemia (AML) has improved significantly over the past decades, from nearly no child surviving to a present probability of cure of approximately 60%. However, this can only be achieved using very intensive chemotherapy which results in relatively high rates of treatment related deaths and significant late effects. This review summarizes current and future classification of pediatric AML, ongoing phase III studies, and subgroup-directed treatment. In addition, the possibilities for more precise risk-group stratification which would allow more tailored and further refined subgroup-directed treatment are discussed. These include minimal residual disease monitoring, pharmacogenomics and the detection of AML-specific molecular abnormalities. Finally, we discuss the opportunities for innovative therapy in pediatric AML, such as the use of novel analogues, monoclonal antibody-mediated drugs, and receptor tyrosine kinase inhibitors. Given the enormous increase in our understanding of the underlying biology of AML, and the development of many new targeted drugs, it should be possible to achieve high-quality cure in nearly all children and adolescents with AML within the next few decades.Keywords
This publication has 100 references indexed in Scilit:
- The incidence and clinical significance of nucleophosmin mutations in childhood AMLBlood, 2007
- Repetitive cycles of high‐dose cytarabine are effective for childhood acute myeloid leukemia: Long‐term outcome of the children with AML treated on two consecutive trials of Tokyo Children's Cancer Study GroupPediatric Blood & Cancer, 2007
- Clinical heart failure in a cohort of children treated with anthracyclines: A long-term follow-up studyEuropean Journal Of Cancer, 2006
- Clinical implications of FLT3 mutations in pediatric AMLBlood, 2006
- Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamicsBlood, 2006
- A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemiaBlood, 2006
- Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification?Blood, 2006
- Ethnicity and survival in childhood acute myeloid leukemia: a report from the Children's Oncology GroupBlood, 2006
- Results of 58872 and 58921 trials in acute myeloblastic leukemia and relative value of chemotherapy vs allogeneic bone marrow transplantation in first complete remission: the EORTC Children Leukemia Group reportLeukemia, 2005
- Allogeneic bone marrow transplantation for children with acute myelocytic leukemia in first remission demonstrates a role for graft versus leukemia in the maintenance of disease-free survivalBlood, 2004